Stanpro Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 5.25 Cr
as on 08-12-2024
- Paid Up Capital ₹ 3.84 Cr
as on 08-12-2024
- Company Age 35 Year, 4 Months
- Last Filing with ROC 31 Mar 2013
- Open Charges ₹ 6.12 Cr
as on 08-12-2024
About Stanpro Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2013. It's a company limited by shares with an authorized capital of Rs 5.25 Cr and a paid-up capital of Rs 3.84 Cr.
The company currently has active open charges totaling ₹6.12 Cr.
Santhanam Jagan, Balan Venkaatesan, Santhanam Vidhya, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231TZ1989PLC003047
- Company No.
003047
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Sep 1989
- Date of AGM
30 Sep 2013
- Date of Balance Sheet
31 Mar 2013
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- LocationCoimbatore - 641 035., Tamil Nadu
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Stanpro Pharmaceutical?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santhanam Jagan  | Director | 22-Dec-2007 | Current |
| Balan Venkaatesan | Director | 12-Mar-2008 | Current |
| Santhanam Vidhya | Director | 12-Mar-2008 | Current |
| Srikanth Santhanam | Director | 22-Dec-2007 | Current |
| Sampath Sudharsan | Director | 23-May-2009 | Current |
Financial Performance of Stanpro Pharmaceutical.
Enhance accessibility to Stanpro Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Stanpro Pharmaceutical?
Unlock access to Stanpro Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
El Os Formusols India Private LimitedActive 24 years 6 monthsSanthanam Jagan and Balan Venkaatesan are mutual person
Charges (Loans)
₹6.12 Cr
₹0
Charges Breakdown by Lending Institutions
- Oriental Bank Of Commerce : 5.62 Cr
- Sona Agencies : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Aug 2009 | Oriental Bank Of Commerce | ₹5.62 Cr | Open |
| 20 Dec 1999 | Sona Agencies | ₹5.04 M | Open |
How Many Employees Work at Stanpro Pharmaceutical?
Unlock and access historical data on people associated with Stanpro Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stanpro Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stanpro Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
